Fermented papaya and Parkinson’s diseaseby Amélie April 22, 2019 0 comments
The possible role of fermented papaya in the treatment of Parkinson’s disease.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons of the sustantia nigra. Although the primary cause of PD is still unknown, converging evidences indicate that oxidative stress is implicated in the development of the disease. Indeed, free radicals my trigger or enhance neurodegenerative process.
There is no disease modifying cure for PD, and the existing therapies only provide symptomatic relief of motor symptoms through improving the dopamine deficit.
Immun’Âge®, made solely of Carica papaya Linn fermentation, is a food supplement with favorable effects on immunological, hematological, inflammatory, and oxydative stress parameters in chronic and degenerative diseases.
Encouraging results for Parkinson’s disease patients
Internal report of Pr Nordera (Italy), 2016 study, Possible role of fermented papaya in the treatment of Parkinson’s disease.
A group of PD patients voluntarly took Immun’Âge® for 3 months. They observed a reduction of motor scores of the Unified Parkinson Disease Rating Scale (UPDRS) and an improvement in activity of daily living performance during treatment.
In addition, they noticed a successive worsening of these parameters after stopping Immun’Âge®. Therfore, they followed prescribing Immun’Âge® in clinical practice, associated with optimized dopaminergic therapy, with good outcomes in terms of tolerabiliy and patient compliance and satisfaction with the treatment.
Although these are only clinical observations, which could be influenced by placebo effect, they do think that Immun’Âge® may be worthy of further investigation to verify its potential effect on PD.
Indeed, Immun’Âge® has been shown to reduce the levels of 8-hydroxydeoxyguanosine (8-OHdG), a biomarker of DNA damage induced by oxydative stress, in other neurodegenerative disorders, such as Alzheimer’s disease.
Noteworthy, 8-OHdG (i.e. DNA damage) levels are selectively increased in the substantia nigra, serum and cerebrospinal fluid of PD patients. Another study by Sato and colleagues showed that PD patients have higher urinary 8-OHdG concentrations compared to healthy age-matched controls. Hence, these levels increase with the severity of the disease.
They confirmed these data, showing that in urine samples, the measurement of 8-OHdG alone as well as the ratio 8-OHdG/2-dG (reflecting oxidative DNA damage) were significantly different in healthy controls and PD patients. In plasma samples, the ratio 8-OHdG/2-dG was significantly higher in PD compared to healthy controls.
In a group of patients taking Immun’Âge® for 3 to 6 months, they observed a reduction of 8-OHdG plasmatic levels (decrease of DNA damage).
Also, in 2011, a clinical study by Hirayama and colleagues pointed out a significant correlation between 8-OHdG levels and motor impairment assessed through UPDRS in PD patients.
Further studies are warranted to clarify the effect of Immun’Âge® on 8-OHdG levels and on motor and functional outcomes in PD.